stroke prevention

High Insulin Resistance Blunts the Superiority of Ticagrelor Over Clopidogrel in Minor Stroke Patients with CYP2C19 Mutations

By MedXY 01/22/2026

A post hoc analysis of the CHANCE-2 trial suggests that the clinical benefit of ticagrelor over clopidogrel for secondary stroke prevention in CYP2C19 loss-of-function carriers is significantly attenuated in patients with high insulin resistance.

Cardiology Neurology news

Genetic Risk Profile Predicts Stroke Prevention Benefit From Continuous Atrial Fibrillation Screening: A Secondary Analysis of the LOOP Study

By MedXY 01/22/2026

A secondary analysis of the LOOP study demonstrates that continuous ECG screening with implantable loop recorders significantly reduces stroke and systemic embolism in individuals with high genetic risk for atrial fibrillation, while potentially increasing bleeding risk in lower-risk cohorts.

Neurology news Radiology

Drug-Coated Balloons Superior to Bare-Metal Stents in Preventing Restenosis for High-Grade Intracranial Atherosclerosis

By MedXY 01/21/2026

A multicenter randomized controlled trial demonstrates that drug-coated balloons significantly reduce 6-month restenosis and 1-year recurrent ischemic events compared to bare-metal stents in patients with symptomatic high-grade intracranial stenotic disease.

Neurology news Radiology

Drug-Coated Balloons Outperform Bare-Metal Stents in Reducing Restenosis for Symptomatic Intracranial Stenosis

By MedXY 01/21/2026

A multicenter RCT demonstrates that drug-coated balloon (DCB) angioplasty significantly reduces 6-month restenosis and 1-year recurrent ischemic events compared to bare-metal stenting in patients with high-grade symptomatic intracranial atherosclerotic disease.

Cardiology Internal Medicine news

Precision Medicine in Atrial Fibrillation: Biomarker-Based ABC-AF Risk Scores Fail to Outperform Standard Care

By MedXY 01/18/2026

A large-scale registry-based RCT reveals that tailoring atrial fibrillation treatment using the biomarker-driven ABC-AF risk score does not significantly reduce stroke or death compared to current standard guideline-based care, highlighting the complexities of implementing precision medicine in clinical practice.

Neurology news

Pushing the Limits: Very Low LDL-C Levels Below 40 mg/dL Proven Safe and Effective for Secondary Stroke Prevention

By MedXY 01/17/2026

A long-term analysis of the FOURIER trials reveals that achieving ultra-low LDL-C levels (<40 mg/dL) significantly reduces recurrent stroke and major cardiovascular events in stroke survivors, without increasing hemorrhagic stroke risk, supporting more aggressive lipid-lowering targets in clinical practice.

Cardiology Neurology news

Novel MicroNet-Covered Stent Sets New Safety Standard for High-Risk Carotid Artery Stenting: Insights from the C-GUARDIANS Trial

By MedXY 01/17/2026

The C-GUARDIANS trial reveals that the CGuard MicroNet-covered stent significantly reduces embolic risks in high-risk carotid artery stenting, achieving a remarkably low 30-day DSMI rate of 0.95% and sustained neuroprotection through one year.

Cardiology Neurology news

Distinct Neuroimaging Signatures: Atrial Fibrillation and Atherosclerosis Drive Divergent Vascular Brain Lesion Patterns

By MedXY 01/05/2026

A large-scale comparative study of 3,508 patients reveals that atrial fibrillation and atherosclerosis produce significantly different vascular brain lesions on MRI, with AF favoring non-lacunar infarcts and periventricular white matter changes, while atherosclerosis is linked to lacunar infarcts and micro-bleeds.

Cardiology Neurology news

Beyond Stenosis: Wall Shear Stress and Oscillatory Index Emerge as Key Biomarkers for High-Risk Carotid Plaques

By MedXY 01/02/2026

A study in Eur Heart J Cardiovasc Imaging identifies elevated systolic wall shear stress and low oscillatory shear index as independent predictors of complicated carotid artery plaques, offering a more precise framework for stroke risk stratification than traditional luminal narrowing assessments.

Neurology news Radiology

Circumferential Aneurysm Wall Enhancement Predicts a Three-Fold Increase in 4-Year Risk of Instability

By MedXY 01/02/2026

A large-scale prospective study in JAMA Neurology identifies circumferential aneurysm wall enhancement (AWE) as a potent independent predictor of intracranial aneurysm growth or rupture, offering a critical radiological biomarker for clinical risk stratification.

Cardiology Neurology news

CREST‑2: Stenting Reduces 4‑Year Ipsilateral Stroke vs Intensive Medical Therapy in Asymptomatic High‑Grade Carotid Stenosis; Endarterectomy Shows No Significant Benefit

By MedXY 11/21/2025

In CREST‑2, patients with ≥70% asymptomatic carotid stenosis randomized to carotid‑artery stenting plus intensive medical therapy had fewer perioperative-or-ipsilateral strokes over 4 years than intensive medical therapy alone; carotid endarterectomy did not show a statistically significant advantage.

Cardiology Neurology Orthopedics

Long-Term Outcomes of Extracranial Vertebral Artery Reconstruction in Managing Symptomatic Vertebral Artery In-Stent Restenosis or Occlusion

By MedXY 10/24/2025

This study evaluates the efficacy of vertebral artery reconstruction surgery versus medical therapy in reducing stroke recurrence and improving neurological outcomes over a ten-year period.

Cardiology news Public Health

Active Monitoring for Atrial Fibrillation (AMALFI): Advancing Long-Term Remote Screening to Reduce Stroke Risk

By MedXY 10/21/2025

The AMALFI trial evaluates remote screening for asymptomatic atrial fibrillation in older adults to improve detection, anticoagulation use, and reduce stroke risk, with findings pending follow-up at 2.5 and 5 years.

Cardiology news Public Health

Remote ECG Patch Screening for Asymptomatic Atrial Fibrillation: Insights from the AMALFI Trial

By MedXY 10/21/2025

The AMALFI trial demonstrates that remote, mail-based 14-day ECG patch screening modestly increases long-term atrial fibrillation detection and anticoagulation use in older adults at stroke risk, with no observed reduction in stroke at 2.5 years.

Cardiology news

Dual Versus Single Antiplatelet Therapy After Valve-in-Valve TAVI: Balancing Stroke Prevention and Bleeding Risk

By MedXY 10/14/2025

This study compares dual and single antiplatelet therapy after valve-in-valve transcatheter aortic valve implantation, finding dual therapy reduces stroke risk without increasing bleeding or valve deterioration at one year.

Cardiology Clinical Updates news Specialties

Low-Dose Apixaban vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion: Insights from the ADALA Trial

By MedXY 09/20/2025

The ADALA randomized trial compared low-dose apixaban with dual antiplatelet therapy post-LAA occlusion, demonstrating superior safety and reduced device-related thrombosis risk with low-dose anticoagulation at 3 months.

Clinical Updates news

Biomarker-Guided ABC-AF Risk Scores: Evaluating Their Role in Personalized Therapy for Atrial Fibrillation

By MedXY 09/06/2025

A large randomized study found that biomarker-based ABC-AF risk score-guided therapy did not improve stroke or death outcomes versus usual care in atrial fibrillation, highlighting the need for rigorous prospective validation of precision medicine tools before clinical adoption.

Cardiology news Pathology & Lab Medicine Specialties

Biomarker-Guided ABC-AF Risk Scores in Atrial Fibrillation: Insights from a Large Multicenter Randomized Trial

By MedXY 09/06/2025

A biomarker-based ABC-AF risk score-guided treatment did not improve stroke or death outcomes versus standard care in atrial fibrillation, underscoring the need for prospective validation of precision medicine tools before clinical implementation.

Cardiology Specialties

Reevaluating Long-Term Anticoagulation After Atrial Fibrillation Ablation: Insights from the ALONE-AF Randomized Trial

By MedXY 09/01/2025

The ALONE-AF trial reveals that discontinuation of oral anticoagulants post-successful atrial fibrillation ablation may reduce stroke, systemic embolism, and major bleeding compared to continued therapy, informing anticoagulation strategies in selected patients.

Cardiology Specialties

Edoxaban as a Safe and Effective Anticoagulant Early After Bioprosthetic Valve Replacement: Insights from the ENBALV Trial

By MedXY 08/17/2025

The ENBALV randomized trial demonstrates that edoxaban offers a potential safe and efficacious alternative to warfarin for anticoagulation within three months after surgical bioprosthetic valve replacement, with comparable thromboembolic event rates and a distinct safety profile.